Login to Your Account



'Highest hurdle' cleared in abuse liability study; Cara readies phase III

By Jennifer Boggs
Managing Editor

Wednesday, October 29, 2014

Cara Therapeutics Inc.'s opioid candidate CR845 passed with flying colors a critical test, demonstrating significantly lower abuse potential compared to a comparator schedule IV narcotic.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription